Skip to main content
Capstone

The Safety of TMP-SMX Use in Patients Taking an ACE-I or ARB

13 August 2016

Abstract

Background: Angiotensin converting enzyme inhibitors (ACE-I) and angiotensin receptor blockers (ARB) are commonly used medications for hypertension, heart failure, and diabetes. Trimethoprim-sulfamethoxazole (TMP-SMX) is a commonly used antibiotic for many bacterial infections. While hyperkalemia is a known risk of each drug, little has been studied about concomitant use of ACE-I/ARBs and TMP-SMX.

Methods: An exhaustive search of MEDLINE-Ovid, Web of Science, Google Scholar, and International Pharmaceutical Abstracts-Ovid using the search terms TMP-SMX and ACE inhibitor and ARB was done. Eligibility criteria included studies in the English language, studies that included concurrent use of TMP-SMX and ACE inhibitors or ARBs, and studies focused on on-label uses of TMP-SMX. Found studies were evaluated using GRADE criteria.

Results: Three studies met eligibility requirements. One retrospective cohort study showed that in patients with renal insufficiency receiving low dose of TMP-SMX, ACE-I/ARB use was a significant risk factor for developing hyperkalemia (adjusted OR 3.95, 95% CI 1.17-13.4). A large nested case-control study found patients taking an ACE-I/ARB prescribed TMP-SMX had an increased risk of hospitalization with diagnosis of hyperkalemia of when compared with those prescribed amoxicillin (adjusted OR 6.7, 95% CI 4.5-10.0). Another large nested case-control drawn from a similar population found patients taking an ACE-I/ARB had an increased risk of sudden death when prescribed TMP-SMX when compared with those prescribed amoxicillin (adjusted OR 1.54, 95% CI 1.29-1.84).

Conclusion: Studies suggest an increased risk with concurrent ACE-I/ARB and TMP-SMX use. As both are commonly prescribed medications, understanding these risks of concomitant use is important. Risks, including hospitalization and sudden death, are likely related to hyperkalemia and likely increase in patients with existing renal insufficiency. Before prescribing TMP-SMX in patients already taking an ACE-I/ARB, clinicians should consider alternatives. More research is needed to fully understand the risks associated with combining these medications.

Keywords: TMP-SMX, ACE inhibitor, Bactrim, trimethoprim-sulfamethoxazole, renin-angiotensin-aldosterone inhibitors, ARB


Files

File nameDate UploadedVisibilityFile size
0-PosterInouye_d4f3ac91-aff9-4955-8b08-149e00533bf8.pdf
19 Mar 2020
Public
597 kB
Main File
19 Mar 2020
Public
727 kB